modalities, such as small molecules, and targets well-characterized biological mechanisms to program the fate and enhance the therapeutic potential of adult stem cells. Our lead product candidate, PROHEMA®, is an ex vivo programmed hematopoietic cellular therapeutic, which is currently in clinical development for patients undergoing hematopoietic stem cell transplantation for the treatment of hematologic malignancies and certain rare genetic disorders. We are also applying our reprogramming modulators to develop human induced pluripotent stem cell-derived cellular therapeutics, and evaluating the in vivo programming of muscle satellite stem cells using our Wnt7a-based protein analogs for muscle regeneration. http://fatetherapeutics.com/about-us/
buran & MARIO |